These symptoms typically improve as the infection clears and treatment progresses
1 Timeline Most stomach and gut symptoms appear in the first one to two weeks after a dose increase, then settle over four to six weeks
Semaglutide and clinical atherosclerotic cardiovascular event data Regulatory authorities recognized that GLP-1 analogues reduce the incidence of MACEs in T2DM patients, but this is only the case for GLP-1R agonists with a molecular structure based on endogenous GLP-1 (semaglutide, liraglutide, albiglutide, and dulaglutide), as they are able to reduce the relative risk of MACEs by up to 10% [43]
However, there have been reports of bronchitis and upper respiratory tract infections in people taking semaglutide
Of note, GLP-1 is also produced locally in the brain, from preproglucagon neurons (Trapp and Brierley, 2022)